Summary Levetiracetam (LEV) is a novel antiepileptic drug (AED) that has recently obtained marketing authorisation for use in children. The purpose of this study was to assess the efficacy, tolerability and retention rate of LEV in children with refractory epilepsies. It is a retrospective multicentre observational study reporting the use of LEV in 200 children, aged 0.3-19 years (median 9-years-old) over a 4-year period.
Introduction
Levetiracetam (LEV) is a novel antiepileptic drug with a unique mechanism of action, 1,2 proven efficacy against partial and generalised seizures, [3] [4] [5] [6] [7] [8] good tolerability and straight forward pharmacokinetics. 9 There have been few studies of LEV use in children, and most are retrospective. Although LEV has been shown to be effective against both partial and generalised epilepsy, with a response rate of up to 50% in children with partial epilepsies, 10 most of the studies contain small numbers and have a limited follow-up period. This study reports the use of LEV in 200 paediatric patients with refractory epilepsies, over a 4-year period. Our results confirm the efficacy and tolerability of LEV in this population and demonstrate good response and retention rates at 12 months.
Methods
Children starting treatment with LEV from December 2001 to December 2004 were ascertained retrospectively from hospital pharmacy and from paediatric neurology databases in four tertiary referral paediatric neurology departments in the Midlands, UK. LEV was prescribed as an ''add on therapy'' for control of refractory epilepsies--partial or generalised, by a Consultant Paediatric Neurologist in each centre.
A retrospective chart review using a standard proforma to assess demographic data, aetiology, epilepsy syndrome, seizure frequency, medication dosage, concomitant AEDs, efficacy and adverse events was recorded at more than 2, 6 and 12 months. Data were analysed using Excel on an intention to treat basis.
Results
Two-hundred children were included in the study. The 59% were male. The majority of our children had early onset epilepsies with a median age of onset of epilepsy of 3 years (range 0-13 years). There was no significant difference between the types of epilepsies treated. The 47% had focal, and 58% had symptomatic epilepsies. Patients commenced on LEV, were aged between 0.3 and 19 years (median 9-years-old).
The intractable nature of the epilepsies treated with LEV is demonstrated by the number of patients who had failed or withdrawn previous AEDs ( Table 1 ). The 76% of children commenced on LEV had been on at least 3 AEDs in the past.
The study comprised 215 person years of LEV exposure. LEV dose ranged from 8 to 100 mg/kg/ day (mean 39 mg/kg).
Brain neuroimaging (either MRI or CT) reports were obtained in 185/200 patients. One-hundred and sixteen (58%) were abnormal (20 with cerebral atrophy, 7 neuro-migrational disorders, 6 cortical dysplasias, 5 hippocampal sclerosis, 4 tuberous sclerosis, 74 (37%) with other abnormalities. The 69 (34.5%) scans were reported as normal.
Seven children achieved LEV monotherapy. Of those patients that achieved monotherapy, five had generalised epilepsies and the majority had been on at least two AEDs in the past (mean 3, range 1-5).
Most patients required at least 1 other AED in addition to LEV and there was no particular preference for a specific combination of AEDs across the centres (Table 2) .
Possibly LEV related adverse events were reported in 24%. The most frequent adverse-effects involved emotional or behavioural changes (Table 3) . Adverse events usually appeared within the first 5 months after treatment initiation. They were not dosedependent and mostly mild. No serious adverse events (death or events requiring hospital admission or a prolongation of hospital admission) were reported. Adverse events generally resolved without medication withdrawal, but if not, did resolve when the medication was stopped. Only 8 of the 200 patients (4%) withdrew from LEV because of adverse events alone.
Some papers have reported increased behavioural adverse events in children and patients with a history of prior behavioural problems. [11] [12] [13] Pre-existing behavioural problems were documented in 8% The 76% of children commenced on LEV had been on at least 3 AEDs in the past. This is an indication of the intractable nature of the epilepsies studied in our group.
(17/200) of children in our study. Of those 17 children only 7 (41%) reported behaviour as a problems on follow-up. The 14% of children who did not have preexisting behavioural difficulties developed new behavioural problems while on LEV. As we did not measure the extent of any behavioural problems we cannot tell if they were worsened on LEV. Therefore, unlike other studies we were unable to detect if behavioural adverse events were more likely to occur in children with pre-existing behavioural difficulties. Eighty-seven children discontinued LEV; discontinuation was due to inefficacy alone in 56 (28%), inefficacy and adverse events in 20 (10%), adverse events alone in 8 (4%) and in 3 for other reasons (parental withdrawal, seizure freedom on introduction of ketogenic diet, seizure freedom post-hemispherotomy) ( Table 4 ). The 22/54 children had an increase in their seizures on LEV. LEV was most likely to be discontinued within the first 3 months of starting the medication (Graph 1).
Data were analysed on 200,195 and 158 children at 2, 6 and beyond 12 months, respectively. The 79% (158/200) patients were followed up beyond 12 months. The 42 children were not followed up at 12 months due to: insufficient data collection, transfer to adult services, and insufficient length of time on LEV. LEV retention for more than 1 year was 49% (76/158). The mean length of time on LEV was 13 months, range (3 weeks-46 months).
Seizure response rates were highest within the first 2 months, with a worthwhile improvement (>50% seizure reduction) of 60% at 2 months, including seizure freedom in 14%. Seizure response rates remained high at 6 months with 40% improved and 14% seizure free. These figures dropped to 32% beyond 12 months with a seizure freedom rate of 5% (Graph 2). Those patients who had an early response tended to maintain that response over the 12 month period.
Discussion
LEV has recently been awarded marketing authorization in the UK for its use in children over 4 years of Retention rate of Levetiracetam in children with intractable epilepsy at 1 year 187 Only seven children achieved LEV monotherapy. The majority of children were on a combination of one or two concomitant AEDs. There was no preference for any particular AED in combination with LEV.
a Gabapentin, phenobarbitone, vigabatrin, prednisalone, zonisamide. Seizure free post-hemispherotomy. Seizure free on introduction of the ketogenic diet. a Maternal withdrawal of medication for alternative therapies.
Graph 1
The 87 children discontinued LEV in total. The 11/87 (9.8%) discontinued LEV within the first month of commencing medication. The % of children who discontinued LEV decreased over time. The highest discontinuation rates of LEV are within the first 3 months of starting the medication. age with partial onset epileptic seizures with or without secondary generalisation. The mechanism of action of LEV remains to be fully elucidated. In vitro studies show that LEV affects intraneuronal Ca 2+ levels by partial inhibition of N-type CA 2+ currents and by reducing the release of Ca 2+ from intraneuronal stores. In addition it partially reverses the reductions in GABA-and glycine-gated currents induced by zinc and b-carbolines.
LEV has been shown to be effective and well tolerated in children with both partial and generalised epilepsies that are difficult to treat. 2, 14, 15 LEV is very straight forward to manage as it has favourable pharmacokinetic characteristics: it has a high oral bioavailability, linear pharmacokinetics and predictable plasma levels, and exhibits no significant drug interactions. 9 This is particularly important in children with intractable epilepsies as many have significant neuropsychiatric co-morbidities including attention deficit/hyperactivity disorder, autisum spectrum disorders, depression, anxiety, and thought disorders. In our study 69% of the patients had co-existent neuropsychiatric disorders or learning difficulties. Only 13.5% had LEV withdrawn due to adverse events. The limitations inherent in data collection with retrospective studies mean it is difficult to retrospectively attribute all of these changes to the addition of an AED alone. Based on published data from prospective, chronic dosing studies, phenobarbitone and topiramate have the highest potential for causing cognitive dysfunction.
14 Although neurobehavioural changes in children with epilepsy may be multifactorial in nature, it is important to monitor the cognitive effect of the addition of an AED. A muticentre prospective study is required to fully asses the effect of LEV on behaviour and cognition.
It has been reported that neurobehavioural adverse events are more common in those children with pre-existing behavioural problems but we were unable to demonstrate that in our study. [15] [16] [17] Preexisting behavioural problems were documented in 8% (17/200) of children in our study. Of those 17 children only 7 (41%) reported behaviour as a problems on follow-up. Due to the inherent limitations of collection of retrospective data, we are unable to comment on whether this is a true improvement or not. A prospective study to highlight the effect of LEV on this subgroup of patients is required.
Continuation rates were a good indicator of efficacy and tolerability. Our results concur with other studies showing an effective early response rate and tolerability of LEV in children with intractable epilepsies. 18, 19 At 2 and 6 months worthwhile improvement (>50% seizure reduction) was noted in 60 and 40%, respectively, including seizure freedom in 14% up to 6 months.
There are a limited number of studies looking at retention rates of LEV in intractable epilepsies for more than 12 months. 20, 21 In this study, the retention rate at more than 12 months was 49%. The 32% of children on LEV for more than 12 months had a >50% improvement in seizure control including a seizure freedom rate of 5%. This is similar to or better than retention rates for add-on therapy with other second line AEDs: Topirimate, Lamotrogine and Gabapentin. 22 The reasons for the discrepancy between retention rates and response rates are difficult to explain retrospectively. It may indicate that patients remained on LEV for beneficial reasons other than seizure control. 23, 24 These benefits need to be studied in more detail prospectively.
Our study confirms the efficacy and tolerability of LEV in children with intractable epilepsies beyond a year. Mutlicentre prospective studies are required to look at the long-term efficacy of LEV beyond this period and to ascertain the relationship between children with pre-existing behavioural difficulties and the potential neurobehavioural adverse effects.
